AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21450587 — intervention group
Group type: COMPARATOR
Intervention: Educational manual for pharmacists (Control)
Number of subjects: 100
Study 15828614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 15828614 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermic route for administration of estrogens
Number of subjects: 0
Study 15828614 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestins
Number of subjects: 0
Study 12144586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg daily for 4 weeks
Number of subjects: 74
Study 12144586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11279910 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-onset headache (onset at or after age 20)
Number of subjects: 1013
Study 11279910 — intervention group
Group type: EXPERIMENTAL
Intervention: Common circumstances of headache onset in adult-onset chronic headache
Number of subjects: 1013
Study 11279910 — intervention group
Group type: EXPERIMENTAL
Intervention: Common factors in adult-onset chronic headache
Number of subjects: 1013
Study 11279910 — intervention group
Group type: EXPERIMENTAL
Intervention: Other factors in adult-onset chronic headache
Number of subjects: 1013
Study 7596697 — intervention group
Group type: EXPERIMENTAL
Intervention: Encopretic patients consuming Ensure meal after overnight fast
Number of subjects: 10
Study 7596697 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming Ensure meal after overnight fast
Number of subjects: 10
Study 2351011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread (GI 100)
Number of subjects: 12
Study 2351011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice (GI 79)
Number of subjects: 12
Study 2351011 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti (GI 61)
Number of subjects: 12
Study 381124 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 33
Study 381124 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 33
Study 31980242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided access
Number of subjects: 635
Study 31980242 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided access
Number of subjects: 635
Study 28833942 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 33
Study 28833942 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA/TDM
Number of subjects: 33
Study 28445354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent saline solution with epinephrine (1:1 million) and lidocaine (0.05%) (group 2)
Number of subjects: 40
Study 28445354 — intervention group
Group type: COMPARATOR
Intervention: Tumescent saline solution with epinephrine (1:1 million) (group 1)
Number of subjects: 40
Study 26626301 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics intervention (tablet A and tablet B)
Number of subjects: 200
Study 24005139 — intervention group
Group type: EXPERIMENTAL
Intervention: Non steroid cream
Number of subjects: 0
Study 24005139 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Number of subjects: 0
Study 21958789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow LVAD (trial group)
Number of subjects: 1982
Study 21958789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow LVAD (posttrial group)
Number of subjects: 1982
Study 21958789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow LVAD (both groups)
Number of subjects: 1982
Study 18245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 258
Study 18245767 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Specialty Referral (ESR)
Number of subjects: 258
Study 18245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IC and ESR
Number of subjects: 258
Study 18245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem drinkers
Number of subjects: 258
Study 18245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonproblematic drinkers
Number of subjects: 258
Study 18245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 258
Study 17154745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage‐matched manuals (MAN)
Number of subjects: 2054
Study 17154745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy plus manuals (NRT + MAN)
Number of subjects: 2054
Study 17154745 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system plus NRT and manuals (EXP + NRT + MAN)
Number of subjects: 2054
Study 17154745 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated counseling plus NRT, manuals, and expert system (TEL + EXP + NRT + MAN)
Number of subjects: 2054
Study 12649521 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.8 hours of therapy per week for 11.2 weeks
Number of subjects: 0
Study 12649521 — intervention group
Group type: COMPARATOR
Intervention: Approximately 2 hours of therapy per week for 22.9 weeks
Number of subjects: 0
Study 12649521 — intervention group
Group type: EXPERIMENTAL
Intervention: Total of 98.4 hours of therapy
Number of subjects: 0
Study 12649521 — intervention group
Group type: COMPARATOR
Intervention: Total of 43.6 hours of therapy
Number of subjects: 0
Study 12649521 — intervention group
Group type: EXPERIMENTAL
Intervention: Total length of therapy time
Number of subjects: 0
Study 12649521 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean change in Porch Index of Communicative Abilities (PICA) scores
Number of subjects: 0
Study 12649521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hours of therapy provided in a week
Number of subjects: 0
Study 12649521 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of hours of therapy
Number of subjects: 0
Study 16104368 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9021334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 25
Study 9021334 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 25
Study 9021334 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Desensitization (SD)
Number of subjects: 25
Study 1576048 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 170,809 (7 mg)
Number of subjects: 8
Study 1576048 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 170,809 (15 mg)
Number of subjects: 8
Study 1576048 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 170,809 (30 mg)
Number of subjects: 8
Study 1576048 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 170,809 (3 mg)
Number of subjects: 8
Study 1576048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2416331 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofisopam (100 mg)
Number of subjects: 36
Study 2416331 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 36
Study 2416331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31878961 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) on a cycle ergometer at home, three times a week for 8 weeks
Number of subjects: 20
Study 31878961 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving an educational intervention and continuing usual treatment
Number of subjects: 20
Study 31878961 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 20
Study 29431785 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucono‐δ‐lactone (GDL) 2000 mg day‐1
Number of subjects: 40
Study 27559939 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of physical-cognitive-mindfulness training
Number of subjects: 112
Study 27559939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study 24440666 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask Supreme (LMA-S)
Number of subjects: 150
Study 24440666 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 150
Study 24440666 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal tube suction-disposable (LTS-D)
Number of subjects: 150
Study 22732470 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free (PSF) intervention
Number of subjects: 145
Study 22732470 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 145
Study 22732470 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance of >=7 sessions
Number of subjects: 145
Study 20157833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg kg(‐1)
Number of subjects: 120
Study 20157833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 microg kg(‐1) + droperidol 100 microg kg(‐1)
Number of subjects: 120
Study 20157833 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.2 ml kg(‐1)
Number of subjects: 120
Study 17899361 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 0
Study 17899361 — intervention group
Group type: COMPARATOR
Intervention: Peer deviance
Number of subjects: 0
Study 15856042 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV
Number of subjects: 598
Study 15856042 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus IFN
Number of subjects: 598
Study 15856042 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU, LEV, and IFN
Number of subjects: 598
Study 12090963 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly enrolled peer leaders
Number of subjects: 235
Study 12090963 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat peer leaders
Number of subjects: 235
Study 12090963 — intervention group
Group type: COMPARATOR
Intervention: Comparison youth
Number of subjects: 235
Study 10599933 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian root extract (VRE) 600 mg LI 156
Number of subjects: 102
Study 10599933 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 102
Study 10599933 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam (FNZ) 1 mg
Number of subjects: 102
Study 8944542 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 20
Study 8944542 — intervention group
Group type: COMPARATOR
Intervention: 2.5% CO2 with oxygen
Number of subjects: 20
Study 8944542 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 with oxygen
Number of subjects: 20
Study 8944542 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CO2 with oxygen
Number of subjects: 20
Study 8944542 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% O2 + 10% CO2
Number of subjects: 20
Study 8944542 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% and 8% CO2 with oxygen
Number of subjects: 20
Study 1742480 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 megaunits (MU)/m2 of human lymphoblastoid interferon-alpha
Number of subjects: 138
Study 1742480 — intervention group
Group type: COMPARATOR
Intervention: 0.2 MU/m2 of human lymphoblastoid interferon-alpha
Number of subjects: 138
Study 7015844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus antacid (Maalox)
Number of subjects: 70
Study 7015844 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus antacid (Maalox)
Number of subjects: 70
Study 30570071 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 69
Study 30570071 — intervention group
Group type: COMPARATOR
Intervention: ANGIO
Number of subjects: 69
Study 26914525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke physiotherapy intervention
Number of subjects: 21
Study 25173770 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian root extract (530 mg per capsule, 1,060 mg daily)
Number of subjects: 61
Study 25173770 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 61
Study 25173770 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian root extract
Number of subjects: 61
Study 23736751 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMT + treatment as usual (TAU)
Number of subjects: 400
Study 23736751 — intervention group
Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 400
Study 21244643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal airflow-inducing manoeuvre (NAIM)
Number of subjects: 25
Study 19739345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lynn's technique (LT)
Number of subjects: 56
Study 19739345 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive approach (MI)
Number of subjects: 56
Study 17908058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program
Number of subjects: 272
Study 17908058 — intervention group
Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 272
Study 15481447 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC collection after intermediate-dose cytarabine and mitoxantrone (group B)
Number of subjects: 75
Study 15481447 — intervention group
Group type: COMPARATOR
Intervention: PBSC collection after induction and/or consolidation chemotherapy (group A)
Number of subjects: 75
Study 11531012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 125 mg/m2
Number of subjects: 14
Study 11531012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 250 mg/m2
Number of subjects: 14
Study 9642024 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral visual field presentation of distractor words and color targets
Number of subjects: 0
Study 9642024 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral visual field presentation of distractor words and color targets
Number of subjects: 0
Study 8029811 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrates (1,500 IU)
Number of subjects: 24
Study 8029811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 2731461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal containing 60 g complex carbohydrates
Number of subjects: 7
Study 2731461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal containing 80 g complex carbohydrates
Number of subjects: 7
Study 2731461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal containing 140 g complex carbohydrates
Number of subjects: 7
Study 30987685 — intervention group
Group type: EXPERIMENTAL
Intervention: m-health medication adherence intervention
Number of subjects: 18
Study 30987685 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study 29324248 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 33
Study 29324248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 27333913 — intervention group
Group type: EXPERIMENTAL
Intervention: High Volume (HV) protocol: 70% 1-RM for sets of 10-12 repetitions with 1-min rest
Number of subjects: 10
Study 27333913 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) protocol: 90% 1-RM for sets of 3-5 repetitions with 3-min rest
Number of subjects: 10
Study 27333913 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 10
Study 25422825 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm long implants
Number of subjects: 24
Study 25422825 — intervention group
Group type: COMPARATOR
Intervention: 10-mm long implants
Number of subjects: 24
Study 23194203 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (25.5 µg/kg/minute)
Number of subjects: 8
Study 23194203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.54 µg/kg/hour)
Number of subjects: 8
Study 23194203 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 8
Study 20576945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 299
Study 20576945 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 299
Study 18831890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tramadol plus adrenaline
Number of subjects: 20
Study 18831890 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine plus adrenaline
Number of subjects: 20
Study 15834304 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized endotoxin removal hemoperfusion cartridge (PMX) for 2 hours (n = 17)
Number of subjects: 36
Study 15834304 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 19)
Number of subjects: 36
Study 15834304 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized endotoxin removal hemoperfusion cartridge (PMX)
Number of subjects: 36
Study 11501687 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.9±2.5 mg/day)
Number of subjects: 12
Study 11501687 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (1.4±0.7 mg/day)
Number of subjects: 12
Study 11501687 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 12
Study 11501687 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 12
Study 9237140 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia resin cement
Number of subjects: 40
Study 9237140 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate cement
Number of subjects: 40
Study 9237140 — intervention group
Group type: EXPERIMENTAL
Intervention: Other two resin cements (not specified)
Number of subjects: 40
Study 8244516 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg PO TID for 7 days)
Number of subjects: 6
Study 8244516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3306095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate containing acetate
Number of subjects: 0
Study 3306095 — intervention group
Group type: COMPARATOR
Intervention: Dialysate containing bicarbonate
Number of subjects: 0
Study 3306095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate containing glucose
Number of subjects: 0
Study 3306095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate without glucose
Number of subjects: 0
Study 3306095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate containing bicarbonate and glucose
Number of subjects: 0
Study 2700702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelaine (3 x 80 mg daily for 6 days)
Number of subjects: 100
Study 2700702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30651161 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtracers™ incorporated into base animal feeds and feed additives during production runs.
Number of subjects: 72
Study 28140752 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-sIPV and RV5 concomitantly (Group 1)
Number of subjects: 192
Study 28140752 — intervention group
Group type: COMPARATOR
Intervention: DTaP-sIPV and RV5 separately (Group 2)
Number of subjects: 192
Study 25881690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Number of subjects: 24
Study 25881690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Mitiglinide + Sitagliptin)
Number of subjects: 24
Study 25881690 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 24
Study 23883803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroid (Ns) + antihistamine (Ah)
Number of subjects: 80
Study 23883803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroid (Ns)
Number of subjects: 80
Study 23883803 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 80
Study 22042283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 100
Study 22042283 — intervention group
Group type: COMPARATOR
Intervention: Low dose intravenous amphotericin B (AmB)
Number of subjects: 100
Study 19536744 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-mouth design
Number of subjects: 0
Study 19536744 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16316744 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide 500 mg/day
Number of subjects: 848
Study 16316744 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide 400-600 mg/day
Number of subjects: 848
Study 16316744 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide (various doses 100-500 mg/day)
Number of subjects: 848
Study 16316744 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide
Number of subjects: 848
Study 15013305 — intervention group
Group type: EXPERIMENTAL
Intervention: IV thymoglobulin (ATG 5 mg/kg/d) plus methylprednisolone (500 mg/d) plus azathiopurine (2 mg/kg/d) on days 0 and 1 after renal transplantation.
Number of subjects: 39
Study 11312402 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthmatics treated with beta(2) agonists alone
Number of subjects: 25
Study 11312402 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthmatics treated with corticosteroids
Number of subjects: 25
Study 11312402 — intervention group
Group type: COMPARATOR
Intervention: Non-asthmatic control subjects
Number of subjects: 25
Study 9562357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (-15 degrees C)
Number of subjects: 8
Study 9562357 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.4 mg x 3) administered 10 min before exercise
Number of subjects: 8
Study 9562357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9562357 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature (23 degrees C)
Number of subjects: 8
Study 7944706 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (1,000 units)
Number of subjects: 21
Study 7944706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antithrombin III supplementation)
Number of subjects: 21
Study 3067339 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine capsules, 1 g b.d. for 6 weeks
Number of subjects: 30
Study 3067339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3067339 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 30
Study 29035633 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology assisted therapy for separation anxiety (TTSA)
Number of subjects: 6
Study 28073668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol treatment
Number of subjects: 399
Study 28073668 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol-free treatment
Number of subjects: 399